AblaCor is developing an innovative ablation system to treat millions of patients with atrial fibrillation (AFib). Success in developing this technology will reduce strokes due to AFib, will improve procedure reliability and make ablation a first-line treatment option. 

RadioEntrepreneur Interview





"Keep the Rhythm"





Advancing Ablation Technology


Abla
Cor Medical Corporation
with an exceptional team of business and technical professionals and endorsement from prominent electrophysiologists and cardiologists, is developing a game-changing, platform technology for the treatment of atrial fibrillation (AF).  The company’s first product, the CircumBlator, is designed to fundamentally improve the treatment for millions of untreated and under-treated patients with atrial fibrillation (AF).  The cause of approximately 20 percent of strokes, AF treatment costs are estimated to be $26 Billion annually in the US alone.  A cornerstone of all catheter ablation procedures, pulmonary vein isolation (PVI) is a key treatment for patients with AF.  The CircumBlator is the first ablation system that will eliminate significant procedural difficulties that occur during PVI procedures when performed with ablation catheters on the market today.